Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

Progress on effects of pharmacogenetics of related transporters on improving the individualized thiopurine therapy

Research progress in toxic effects of antitumor drugs based on drug transporter

Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

[Personalized Dosing from Perspective of Pharmacogenomics of Drug Metabolizing Enzymes and Transporters].

Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients

Progress in research of cytochrome P450 3A4 gene polymorphism

Effects of genetic and clinical factors on thiopurine drugs pharmacokinetics in Tunisian patients

Influence of genetic polymorphisms on pharmacokinetics and treatment response of mycophenolic acid: a scoping review

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti–PD‐1 and Anti‐CD137 Monoclonal Antibodies

P096 Combined Detection Variants of NUDT15 Could Highly Predict Thiopurine-Induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease: a Multi-Center Analysis

Age differences in lactic and malic dehydrogenases in the rat.

Personalized immunosuppressive therapy in pediatric heart transplantation: Progress, pitfalls and promises.

Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs

P469 Effectiveness of Dose Optimisation by Pre-Genotyping NUDT 15 R139C on Reducing Thiopurine-Induced Leucopoenia in Chinese Patients with Crohn’s Disease: a Randomised Controlled Trial

Pharmacogenomics-a New Frontier for Individualized Treatment of Parkinson's Disease

The predictive value of UGT1A gene polymorphism on irinotecan induced toxicity and effect in Chinese me-tastatic colorectal carcinoma

Thiopurine Methyltransferase Gene Polymorphisms in Chinese Patients with Inflammatory Bowel Disease

Perforation of the urinary bladder due to prolonged use of an indwelling catheter.

Safety and efficacy of personalized versus standard initial dosing of thiopurines: Systematic review and meta-analysis of randomized trials